Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(83%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_1
2
33%
Ph phase_2
3
50%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Active, not recruiting5
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting583%
completed117%

Recent Activity

5 active trials
Showing 5 of 6
active_not_recruitingphase_2

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420
active_not_recruitingphase_1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051
active_not_recruitingphase_2

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378
active_not_recruitingphase_1

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

NCT04446351
active_not_recruitingphase_3

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06062420Phase 2

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Active Not Recruiting
NCT05277051Phase 1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT05565378Phase 2

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Active Not Recruiting
NCT04446351Phase 1

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT06472076Phase 3

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT06926673Phase 2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6